{Reference Type}: Case Reports
{Title}: Allergic bronchopulmonary aspergillosis in a lung transplant recipient treated with mepolizumab.
{Author}: Ioakeim F;Abellan C;Casutt A;Lechartier B;Noirez L;Beigelman-Aubry C;Aubert JD;Balmpouzis Z;Koutsokera A;
{Journal}: Clin Immunol
{Volume}: 264
{Issue}: 0
{Year}: 2024 Jul 25
{Factor}: 10.19
{DOI}: 10.1016/j.clim.2024.110265
{Abstract}: Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction to Aspergillus spp. ABPA diagnosis may be challenging due to its non-specific presentation. Standard ABPA treatment consists of systemic corticosteroids and antifungal agents. Mepolizumab, a monoclonal antibody against interleukin-5 seems to be a promising treatment for ABPA. Data about ABPA following lung transplantation (LuTx) are scarce. LuTx recipients are at higher risk for adverse effects of ABPA treatment compared to the general population. Here we present a case of a LuTx recipient who was successfully treated with mepolizumab for ABPA following LuTx. Prolonged administration of high dose prednisone was thus avoided. To our knowledge, this is the first case describing mepolizumab administration following LuTx. Mepolizumab seems particularly attractive as a corticosteroid-sparing agent or as an alternative option to antifungal treatments, because of its excellent safety profile and low risk of drug interactions.